Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 7 min read

  1. Stone PC, Minton O, Richardson A, Buckle P, Enayat ZE, Marston L, Freemantle N. Methylphenidate versus placebo for treating fatigue in people with advanced cancer: randomized, double-blind, multi-center, placebo-controlled trial. J Clin Oncol 2024;42:2382–93. 10.1200/JCO.23.02639
  2. Al Maqbali M, Al Sinani M, Al Naamani Z, Al Badi K, Tanash MI. Prevalence of fatigue in patients with cancer: a systematic review and meta-analysis. J Pain Symptom Manage 2021;61:167–89.e14.32768552
  3. Stone P, Candelmi DE, Kandola K, Montero L, Smetham D, Suleman S, et al. Management of fatigue in patients with advanced cancer. Curr Treat Options Oncol 2023;24:93–107.36656503
  4. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971–6.11038033
  5. O’Higgins CM, Brady B, O’Connor B, Walsh D, Reilly RB, et al. The pathophysiology of cancer-related fatigue: current controversies. Support Care Cancer 2018;26:3353–64.29961146
  6. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Sys Rev 2010;2010:CD006704.
  7. Roila F, Fatigoni S. Fatigue. In Bosnjak S, Bozovic-Spasojevic I, Mountzios G, Wood J, editors. ESMO Handbook of Supportive and Palliative Care. Lugano, Switzerland: ESMO Press; 2022. pp. 175–81.
  8. Toohey K, Chapman M, Rushby AM, Urban K, Ingham G, Singh B. The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis. J Cancer Surviv 2023;17:399–415.35040076
  9. Wang P, Wang D, Meng A, Zhi X, Zhu P, Lu L, et al. Effects of walking on fatigue in cancer patients: a systematic review and meta-analysis. Cancer Nurs 2022;45:E270–8.34870943
  10. Corbett TK, Groarke A, Devane D, Carr E, Walsh JC, McGuire BE, et al. The effectiveness of psychological interventions for fatigue in cancer survivors: systematic review of randomised controlled trials. Syst Rev 2019;8:324.31836007
  11. Poort H, Peters M, Bleijenberg G, Gielissen MF, Goedendorp MM, Jacobsen P, et al. Psychosocial interventions for fatigue during cancer treatment with palliative intent. Cochrane Database Syst Rev 2017;7:CD012030.
  12. Kimko H, Cross T, Abernethy D. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37:457–70.10628897
  13. Dopheide J, Pliszka S. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy: J Human Pharmacol Drug Therapy 2009;29:656–79.
  14. Belloni S, Arrigoni C, de Sanctis R, Arcidiacono MA, Dellafiore F, Caruso R. A systematic review of systematic reviews and pooled meta-analysis on pharmacological interventions to improve cancer-related fatigue. Crit Rev Oncol Hematol 2021;166:103373.34051301
  15. Mochamat MM, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Sys Rev 2015. 10.1002/14651858.CD006788.pub3
  16. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 2009;38:650–62.19896571
  17. Richard PO, Fleshner NE, Bhatt JR, Hersey KM, Chahin R, Alibhai SMH, et al. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int 2015;116:744–52.24684534
  18. Pedersen L, Lund L, Petersen MA, Sjogren P, Groenvold M. Methylphenidate as needed for fatigue in patients with advanced cancer. A prospective, double-blind, and placebo-controlled study. J Pain Symptom Manage 2020;60:992–1002.32464260
  19. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006;24:2073–8.16648508
  20. Bruera E, Yennurajalingam S, Palmer JL, Perez-Cruz PE, Frisbee-Hume S, Allo JA, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol 2013;31:2421–7.23690414
  21. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010;28:3673–9.20625123
  22. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008;16:577–83.17972110
  23. Butler JM Jr, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007;69:1496–501.17869448
  24. Centeno C, Roji R, Portela MA, De Santiago A, Cuervo MA, Ramos D, et al. Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo. BMJ Support Palliat Care 2022;12:226–34.
  25. Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2010;116:5102–10.20665492
  26. Yellen S, Cella D, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74.9095563
  27. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, et al. EORTC QLQ-C15-PAL: the new standard in the assessment of health-related quality of life in advanced cancer? Palliat Med 2006;20:59–61.16613400
  28. EuroQol-Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.10109801
  29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.6880820
  30. Jaeschke R, Guyatt GH, Keller J, Singer J. Interpreting changes in quality-of-life score in N of 1 randomized trials. Control Clin Trials 1991;12:226S–33S.1663858
  31. Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC, Zhang K, et al. Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 2007;10:1068–75.17985963
  32. Gong S, Sheng P, Jin H, He H, Qi E, Chen W, et al. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLOS ONE 2014;9:e84391.24416225
  33. Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 2011;41:761–7.21251796
  34. Roji R, Stone P, Ricciardi F, Candy B. Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression. BMJ Support Palliat Care 2020;10:385–94.
  35. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, Sweetenham J, et al. Epoetin Alfa Study G. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335–45.12565986
  36. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.11387359
  37. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547–61.12551804
  38. Hui D, Arthur J, Dalal S, Bruera E. Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials. Support Care Cancer 2012;20:1779–85.21935717
  39. Chen EK, Riffin C, Reid MC, Adelman R, Warmington M, Mehta SS, et al. Why is high-quality research on palliative care so hard to do? Barriers to improved research from a survey of palliative care researchers. J Palliat Med 2014;17:782–7.24885960
  40. Clark J, Gardiner C, Barnes A. International palliative care research in the context of global development: a systematic mapping review. BMJ Support Palliat Care 2018;8:7–18.
  41. Cancer Research UK. Cancer Mortality Statistics. 2023. URL: www.cancerresearchuk.org/cancer-info/cancerstats/mortality/ (accessed 16 February 2024).
  42. Wilcock A, Howard P, Charlesworth S, editors. Palliative Care Formulary. 8th edn. London, UK: Royal Pharmaceutical Press; 2022. p. 976.
  43. NCCN. NCCN Clinical Practice Guidelines in Oncology: Cancer Related Fatigue. 2023. URL: www.nccn.org/guidelines/category_3 (accessed 16 February 2024).
  44. Fabi A, Bhargava R, Fatigoni S, Guglielmo M, Horneber M, Roila F, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol 2020;31:713–23.32173483
  45. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, et al.; American Society of Clinical Oncology. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 2014;32:1840–50.24733803
  46. Chow R, Bruera E, Sanatani M, Chiu L, Prsic E, Boldt G, Lock M. Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. Support Palliat Care 2021;13:274–80.
  47. Yennurajalingam S, Basen-Engquist K, Reuben JM, Fellman BM, Shete S, Maddi R, et al. Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study. Support Care Cancer 2022;30:497–509.34331589
  48. Luo WT, Huang TW. Effects of ginseng on cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials. Cancer Nurs 2022;46:120–7.35184068
  49. Tomlinson D, Robinson PD, Oberoi S, Cataudella D, Culos-Reed N, Davis H, et al. Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis. Curr Oncol 2018;25:e152–67.29719440
← ConclusionsAdditional information →

Attribution. Patrick Stone; Ollie Minton; Alison Richardson; Peter Buckle; Zinat E Enayat; Louise Marston et al. (2025). Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial. National Institute for Health and Care Research. Copyright © 2025 Stone et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK616759. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support